Aubameyang lands in London for Arsenal medical

982 0
982 0
Pierre-Emerick Aubameyang: now in London for Arsenal medical

Pierre-Emerick Aubameyang’s £55million move to Arsenal edged closer on Tuesday after he was  spotted arriving at Arsenal’s  London Colney base where he will undergo his medical.

The Borussia Dortmund striker was earlier seen  leaving Dortmund Airport.

In Dortmund, the Gabon international, who has been the subject of intense interest this month from the Gunners, was spotted gathering his belongings from a gold Range Rover before heading towards a back entrance.

Aubameyang, left, with his dad, second left and brothers at Dortmund Airport

The 28-year-old forward then flew to Luton Airport on a private jet, accompanied by his father Pierre and his brothers Catilina and Willy, to finalise the move, which will see him become Arsenal’s club-record signing.

The Gabon striker withdrew on Monday from appearing as a witness at a court case of the man suspected of targeting Dortmund’s bus with three bombs last April.

Officially, Aubameyang is sick and cannot attend and Dortmund have given him permission to stay away.

And now it looks like his departure is imminent, with the Arsenal-bound forward part of a striker merry-go-round.

Arsenal’s signing of Aubameyang will only be sanctioned once London rivals Chelsea secure Olivier Giroud and loan out Michy Batshuayi.

In a complicated chain of sale, Dortmund insist they will only sign off the 28-year-old Aubameyang’s release once they have a replacement. They have targeted Batshuayi on loan and Chelsea will agree to that if they can sign Giroud.

On Monday, it looked as if Chelsea were using that to try to drive down the price for the Frenchman. Chelsea have offered £15m plus add-ons but are still short of the £30m valuation as the Gunners demand a premium price for selling to their London rivals.

Once a deal for Giroud is in place, Chelsea will allow Batshuayi to sign for Dortmund on loan, subsequently triggering Aubameyang’s move to the Gunners.

 

 


Join the Conversation